Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study

Belantamab mafodotin (BM) is an anti-BCMA antibody-drug conjugate (GSK2857916) that represents an alternative option in multiple myeloma. We sought to assess the efficacy and safety of BM in a real-world setting in patients who benefited from an early access program. We conducted an observational, r...

Descripción completa

Detalles Bibliográficos
Autores principales: Talbot, Alexis, Bobin, Arthur, Tabone, Léa, Lambert, Jérôme, Boccaccio, Catherine, Deal, Cécile, Petillon, Marie-Odile, Allangba, Olivier, Agape, Philippe, Arnautou, Pierre, Belkhir, Rakiba, Cailleres, Sylvie, Chaoui, Driss, Chrétien, Marie-Lorraine, Decaux, Olivier, Schulmann, Samantha, Frenzel, Laurent, Gastaud, Lauris, Huart, Antoine, Hulin, Cyrille, Karlin, Lionel, Laribi, Kamel, Le Calloch, Ronan, Lenain, Pascal, Macro, Margaret, Manier, Salomon, Montes, Lydia, Moreau, Stéphane, Moreau, Philippe, Morel, Véronique, Norwood, James, Piocelle, Frédérique Orsini, Perrot, Aurore, Pica, Gian Matteo, Rey, Philippe, Schmitt, Anna, Stoppa, Anne-Marie, Tiab, Mourad, Touzeau, Cyrille, Vidal, Valérie, Vignon, Marguerite, Vincent, Laure, Van De Wyngaert, Zoé, Zarnitsky, Charles, Kerbouche, Naima, Paka, Prani, Leleu, Xavier, Arnulf, Bertrand, Avet-Loiseau, Hervé
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2023
Materias:
Article - Plasma Cell Disorders
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543185/
https://www.ncbi.nlm.nih.gov/pubmed/37078253
http://dx.doi.org/10.3324/haematol.2022.281772

Ejemplares similares

Ejemplares similares